CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00846027
NCT00846027Phase 2Completed
CompareCT.gov

An Open Label Study to Assess the Effect of First Line Treatment With Avastin in Combination With Paclitaxel and Gemcitabine in Progression-free Survival in Patients With HER-2 Negative Breast Cancer

Hoffmann-La Roche·interventional·Posted Feb 18, 2009·Updated Jul 23, 2014

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, Paclitaxel, and 1 other intervention for Breast Cancer. Completed, enrolled 90 participants across 23 sites.

Detailed Summary

This single-arm study assessed the efficacy and safety of first-line treatment with Avastin (bevacizumab) in combination with taxane-based chemotherapy (paclitaxel and gemcitabine) in patients with HER-2 negative breast cancer. Patients received Avastin 10 mg/kg iv, paclitaxel 150 mg/m\^2 iv, and gemcitabine 200 mg/m\^2 iv on Day 1 and Day 15 of each 4-week treatment cycle until disease progression, death, or withdrawal of consent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSpain
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2009
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.4 years ago

Interventions

Bevacizumabdrug

Bevacizumab was supplied as a sterile liquid in glass vials.

Paclitaxeldrug

Paclitaxel was supplied as a sterile liquid in glass vials.

Gemcitabinedrug

Gemcitabine was supplied as a sterile liquid in glass vials.